Syndax Pharmaceuticals, Inc. Q1 FY2026 earnings call

Commercial front: Delivered strong sales of Revuforge and Nictimbo. Revuforge had double-digit growth, driven by new NPM1 patients and expanded label. Nictimbo had consistent new patient starts. Pipeline: Made progress in advancing Revimentib's pivotal frontline trials, with global site activation and patient enrollment. Upcoming data readouts at medical meetings. R&D: Focused on advancing Revumenib trials, axotilamab development with upcoming data readouts in IPF and chronic GVHD.

In the first quarter, combined sales of Revuforge and Nictimbo were over $100 million. Revuforge net revenue totaled $49 million, with double-digit quarter-over-quarter growth driven by new NPM1 patients. Nictimbo delivered $55 million in net revenue. Revuforge's revenue contribution is from its strong performance in NPM1 and KMT2A segments, while Nictimbo's is from chronic GVHD. Revuforge annualizes to nearly $200 million, and Nictimbo annualizes to over $200 million.

Expect continued growth in Revuforge as adoption in NPM1 increases and average duration of therapy extends. Nictimbo to continue growing as patient mix evolves and important readouts later this year. Total R&D plus SG&A expenses in 2026 expected to be approximately $400 million, excluding non-cash stock compensation. Well-funded to invest in commercialization and development.

Questions from analysts about Revuforge's real-world study, KMT2A market penetration, NPM1 gating factors, transplant maintenance dynamics, axotilamab trial timelines, first line AML phase three trials, IPF investigator interest, RAVEN study, Revenue Forge access, and NUP98 opportunity, with responses from company executives